Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Enterprise Value (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Enterprise Value for 9 consecutive years, with -$848.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 13.71% to -$848.2 million in Q3 2025 year-over-year; TTM through Dec 2025 was -$2.3 billion, a 172.08% decrease, with the full-year FY2024 number at -$832.3 million, up 19.54% from a year prior.
  • Enterprise Value was -$848.2 million for Q3 2025 at Denali Therapeutics, down from -$757.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$485.7 million in Q2 2021 to a low of -$1.4 billion in Q1 2021.
  • A 5-year average of -$937.4 million and a median of -$876.3 million in 2024 define the central range for Enterprise Value.
  • Biggest YoY gain for Enterprise Value was 41.12% in 2021; the steepest drop was 272.16% in 2021.
  • Denali Therapeutics' Enterprise Value stood at -$865.4 million in 2021, then tumbled by 54.4% to -$1.3 billion in 2022, then grew by 22.58% to -$1.0 billion in 2023, then rose by 19.54% to -$832.3 million in 2024, then dropped by 1.91% to -$848.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Enterprise Value are -$848.2 million (Q3 2025), -$757.7 million (Q2 2025), and -$761.0 million (Q1 2025).